EDIT Stock Cash Flow Statements

Editas Medicine Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Editas Medicine Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31

cash flow from operating activities
net income	-53,235,000	-76,088,000	-45,395,000	-62,141,000	-67,607,000	-61,950,000	-18,874,000	-45,019,000	-40,290,000	-49,036,000	-60,738,000	-55,726,000	-53,453,000	-50,515,000	-41,436,000	-39,082,000	-55,256,000	-56,728,000	-62,499,000	7,819,000	-23,572,000	-37,724,000	-37,770,000	-32,941,000	-33,786,000	-29,249,000	-25,055,000	-15,238,000	-38,722,000	-30,939,000		-26,599,000	-26,439,000	-31,097,000		-21,020,000	-19,042,000	-17,745,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	2,664,000	2,979,000	4,020,000	4,802,000	5,010,000	7,585,000	5,345,000	4,731,000	5,215,000	4,507,000	5,364,000	5,881,000	6,618,000	11,431,000	7,657,000	10,012,000	13,526,000	12,204,000	5,673,000	5,846,000	5,417,000	6,220,000	6,336,000	6,559,000	6,493,000	7,855,000	6,347,000	6,699,000	7,024,000	6,528,000		4,467,000	5,016,000	5,804,000		3,690,000	5,199,000	4,210,000
depreciation	1,834,000	1,917,000	1,381,000	1,599,000	1,420,000	1,409,000	1,466,000	1,514,000	1,540,000	1,544,000	1,577,000	1,604,000	1,598,000	1,558,000	1,511,000	1,190,000	1,189,000	1,163,000	1,183,000	1,107,000	871,000	798,000	782,000	727,000	693,000	628,000	880,000	839,000	784,000	751,000		684,000	651,000	631,000		281,000	246,000	187,000
loss on disposal of fixed assets			10,000					0	0	1,583,000
net amortization of premiums and discounts on marketable securities	-257,000	-583,000	-869,000	-1,326,000	-1,880,000	-1,716,000	-2,103,000
interest related to sale of future revenues	2,091,000	2,145,000
impairment of held for sale assets	0	3,724,000
other non-cash items	-882,000	492,000	0	0					-780,000	-693,000	-498,000	-283,000	-177,000	234,000	325,000	422,000	509,000	401,000	389,000	4,000	-74,000	-215,000	-501,000	-468,000	-778,000	-1,181,000	-1,139,000	-1,031,000	-668,000	-430,000		-193,000	107,000	69,000
changes in operating assets and liabilities:
accounts receivable	-78,000	15,756,000	-16,140,000	118,000	1,000	9,942,000	-7,765,000	-136,000	-2,044,000	4,903,000	-5,025,000	593,000	659,000	-1,105,000	-16,000	80,000	341,000	5,376,000	-4,993,000	810,000	-33,000	-1,414,000	-107,000	-299,000	-12,000	30,000	13,000	319,000	569,000	-252,000		125,000	125,000	-857,000		73,000	-87,000	-89,000
prepaid expenses and other current assets	-488,000	70,000	2,789,000	1,072,000	2,142,000	-1,607,000	-968,000	160,000	-947,000	1,558,000	-444,000	1,215,000	-809,000	-99,000	2,317,000	-4,107,000	903,000	4,618,000	-462,000	-927,000	-1,259,000	-1,995,000	-758,000	-38,000	-488,000	789,000	-1,061,000	-935,000	-653,000	-761,000		228,000	-972,000	486,000		-80,000	-499,000	-1,088,000
right-of-use assets	2,569,000	6,125,000	3,174,000	1,223,000	-5,508,000	2,237,000	-1,744,000	2,875,000	1,533,000	7,304,000	-21,116,000	-1,866,000	2,791,000	2,716,000	2,611,000	2,513,000	8,744,000	-4,177,000	1,270,000	2,171,000	-1,547,000	1,739,000
other non-current assets	0	1,025,000	60,000	2,863,000	1,342,000	-899,000	-2,833,000			-1,500,000	2,277,000	0	-214,000	-505,000	-31,000	0	-92,000	-1,985,000	-825,000	13,000	0	93,000	-1,000				0	0				0	0	2,000		11,000	-24,000	2,248,000
accounts payable	1,258,000	-27,000	-6,999,000	-1,254,000	7,423,000	-1,456,000	-2,594,000	2,358,000	-699,000	-557,000	2,694,000	422,000	1,481,000	-229,000	1,839,000	-1,160,000	-3,835,000	2,017,000	1,302,000	-1,473,000	-3,741,000	4,767,000	-731,000	2,464,000	-2,085,000	626,000	113,000	683,000	-4,111,000	5,095,000		-803,000	-6,712,000	10,078,000		-2,164,000	3,715,000	544,000
accrued expenses	578,000	1,693,000	17,146,000	1,015,000	-3,844,000	-2,694,000	4,092,000	2,382,000	-3,787,000	1,427,000	10,990,000	-887,000	4,384,000	-3,982,000	5,273,000	-3,423,000	3,547,000	-9,563,000	4,098,000	10,048,000	1,205,000	-13,644,000	13,976,000	136,000	2,296,000	-6,923,000	1,698,000	312,000	3,284,000	-1,252,000		-2,762,000	4,339,000	-10,539,000		1,900,000	320,000	1,814,000
accrued interest on sale of future revenues	0	-2,128,000
deferred revenue	-2,000,000	-4,221,000									0	0	2,183,000	-5,516,000	-11,334,000	-5,666,000	-151,000	-5,555,000	-5,768,000	-78,651,000	-3,066,000	-4,309,000	58,323,000	-3,549,000	2,682,000	-2,061,000	18,501,000	511,000	7,019,000	-3,142,000		-3,103,000	-2,277,000	90,214,000		158,000	163,000	158,000
operating lease liabilities	-5,149,000	-3,899,000	-3,456,000	-210,000	4,558,000	-2,396,000	1,925,000	-2,575,000	48,000	-6,808,000	22,646,000	1,043,000	-2,906,000	-3,215,000	-3,298,000	-1,564,000	-8,382,000	2,750,000	-575,000	-2,093,000	1,624,000	-1,902,000
other non-current liabilities	-1,310,000	3,221,000		-488,000
net cash from operating activities	-50,212,000	-47,799,000	-50,762,000	-52,588,000	-57,062,000	-49,872,000	-22,240,000	-35,459,000	-38,711,000	-35,768,000	-42,273,000	-48,004,000	-37,845,000	-49,227,000	-34,582,000	-40,785,000	-38,957,000	-49,479,000	-40,100,000	-54,801,000	-30,856,000	-54,086,000	41,024,000	-26,884,000	-25,806,000	-29,003,000	1,327,000	-7,841,000	-16,733,000	-22,460,000		-27,977,000	-26,162,000	69,791,000		-17,041,000	-9,899,000	-9,629,000
capex	0	-114,000	-540,000	-2,921,000	-3,494,000	-1,871,000	-1,307,000	-239,000	-1,333,000	-1,840,000	-624,000	-614,000	-632,000	-2,248,000	-2,845,000	-2,344,000	-2,704,000	-84,000	-1,376,000	-1,793,000	-1,841,000	-2,152,000	-1,691,000	-2,245,000	-1,513,000	-718,000	-1,415,000	-938,000	-1,390,000	-1,011,000		-752,000	-362,000	-656,000		-713,000	-1,161,000	-943,000
free cash flows	-50,212,000	-47,913,000	-51,302,000	-55,509,000	-60,556,000	-51,743,000	-23,547,000	-35,698,000	-40,044,000	-37,608,000	-42,897,000	-48,618,000	-38,477,000	-51,475,000	-37,427,000	-43,129,000	-41,661,000	-49,563,000	-41,476,000	-56,594,000	-32,697,000	-56,238,000	39,333,000	-29,129,000	-27,319,000	-29,721,000	-88,000	-8,779,000	-18,123,000	-23,471,000		-28,729,000	-26,524,000	69,135,000		-17,754,000	-11,060,000	-10,572,000
cash flow from investing activities
purchases of property and equipment	0	-114,000	-540,000	-2,921,000	-3,494,000	-1,871,000	-1,307,000	-239,000	-1,333,000	-1,840,000	-624,000	-614,000	-632,000	-2,248,000	-2,845,000	-2,344,000	-2,704,000	-84,000	-1,376,000	-1,793,000	-1,841,000	-2,152,000	-1,691,000	-2,245,000	-1,513,000	-718,000	-1,415,000	-938,000	-1,390,000	-1,011,000		-752,000	-362,000	-656,000		-713,000	-1,161,000	-943,000
proceeds from the sale of equipment											0	0							-9,000	7,000			66,000	0	0	36,000	19,000	13,000	0	5,000
purchases of marketable securities			4,000	0	3,000	-86,224,000	-38,753,000	-151,581,000	-27,385,000	-40,798,000	-105,404,000	-26,263,000	-123,138,000	-60,381,000	-104,321,000	-110,443,000	-66,705,000	-127,422,000	-158,041,000	-233,979,000	0	-66,384,000	-37,057,000	-198,557,000	-31,877,000	-74,692,000	-108,208,000	-126,697,000	-171,791,000	-52,674,000		-117,610,000
proceeds from maturities of marketable securities	42,499,000	56,501,000	31,494,000	86,900,000	55,445,000	83,350,000	102,900,000	49,000,000	41,700,000	65,905,000	78,500,000	116,104,000	119,750,000	119,000,000	84,326,000	73,126,000	74,200,000	130,750,000	30,500,000	83,500,000	76,000,000	115,000,000	46,500,000	78,500,000	109,500,000	126,000,000	101,000,000	114,000,000	101,500,000	94,500,000
net cash from investing activities	42,650,000	56,387,000	30,958,000	83,979,000	51,954,000	-4,745,000	62,840,000	-102,820,000	12,982,000	23,267,000	-27,528,000	89,227,000	-4,002,000	56,371,000	-22,840,000	-39,661,000	4,791,000	3,244,000	-108,894,000	-152,265,000	74,173,000	46,464,000	7,818,000	-122,302,000	76,110,000	50,626,000	-8,604,000	-13,622,000	-71,681,000	40,820,000		-28,847,000	-180,985,000	-656,000		-713,000	-1,161,000	-2,562,000
cash flow from financing activities
repayment on sale of future revenues	0	-2,872,000
proceeds from issuance of common stock from at the market equity offering	7,184,000	1,435,000
proceeds from exercise of stock options			1,000	0	0	192,000	30,000	0			7,000	80,000	0	218,000	430,000	2,496,000	16,567,000	12,002,000	8,668,000	947,000	6,839,000	3,047,000	9,107,000	2,137,000	2,086,000	1,533,000	1,952,000	1,451,000	2,515,000	4,410,000		45,000	55,000	435,000
proceeds from issuance of common stock under employee stock purchase plan				0				0
net cash from financing activities	7,412,000	-1,437,000	55,513,000	0	322,000	192,000	514,000	0			619,000	80,000	367,000	218,000	1,057,000	2,496,000	17,082,000	261,471,000	9,100,000	822,000	211,153,000	3,047,000	84,569,000	43,353,000	2,369,000	1,533,000	30,352,000	1,240,000	2,667,000	52,681,000		-730,000	-309,000	97,094,000		-22,000	-494,000	98,215,000
net increase in cash, cash equivalents, and restricted cash	-150,000	7,151,000					41,114,000	-138,279,000	91,796,000	-12,501,000	-69,182,000	41,303,000	-41,480,000	7,362,000	-56,365,000	-77,950,000	-17,084,000	215,236,000	-139,894,000	-206,244,000	254,470,000	-4,575,000
cash, cash equivalents, and restricted cash, beginning of period	0	135,418,000	0	0	0	127,529,000	0	0	0	145,399,000	0	0	0	207,396,000	0	0	0	143,559,000	0	0	0	239,802,000
cash, cash equivalents, and restricted cash, end of period	-150,000	142,569,000	35,709,000	31,391,000	-4,786,000	73,104,000	41,114,000	-138,279,000	91,796,000	132,898,000	-69,182,000	41,303,000	-41,480,000	214,758,000	-56,365,000	-77,950,000	-17,084,000	358,795,000	-139,894,000	-206,244,000	254,470,000	235,227,000
cash and cash equivalents, end of period	-150,000	138,692,000	35,709,000	31,391,000	-4,786,000	69,227,000																										-57,554,000	-207,456,000	351,552,000		-17,776,000	-11,554,000	229,204,000
restricted cash1	0	3,877,000	0	0	0	3,877,000
1 as of march 31, 2025 and march 31, 2024, restricted cash of 3,877 and 3,877 was included in restricted cash and other non-current assets on the consolidated balance sheet, respectively.
non-cash interest expense on liability for sale of future revenues
other current and non-current liabilities						1,673,000													-3,136,000	-891,000	511,000	833,000	1,124,000	525,000	-878,000	881,000
proceeds from offering of common stock, net of issuance costs							0	0							1,000	0	-11,000	249,469,000	-113,000	-125,000			75,125,000				28,318,000	0	-3,000	48,474,000
proceeds from sale of future revenues
issuance of common stock under benefit plans											612,000	0			626,000	0			545,000	0
1as of december 31, 2024, december 31, 2023, and december 31, 2022 restricted cash of 3,877, 3,877, and 3,877, respectively, was included in restricted cash and other non-current assets on the consolidated balance sheet
net decrease in cash, cash equivalents, and restricted cash						-54,425,000
1 as of september 30, 2024, restricted cash of 3,877 was included in restricted cash and other non-current assets on the consolidated balance sheet
1 as of september 30, 2023, restricted cash of 3,878 was included in restricted cash and other non-current assets on the consolidated balance sheet
supplemental disclosure of cash and non-cash activities:
1 as of june 30, 2024, restricted cash of 3,877 was included in restricted cash and other non-current assets on the consolidated balance sheet
1 as of june 30, 2023, restricted cash of 3,877 was included in restricted cash and other non-current assets on the consolidated balance sheet
1 first quarter 2024 restricted cash of 3,877 was included in restricted cash and other non-current assets on the consolidated balance sheet
1 first quarter of 2023 restricted cash of 3,877 was included in restricted cash and other non-current assets on the consolidated balance sheet
fixed asset additions included in accounts payable and accrued expenses						1,644,000	646,000	-13,000	-158,000	370,000	1,027,000	286,000	-72,000	199,000	152,000	-482,000	612,000	467,000	-254,000	481,000	-276,000	705,000	-44,000	676,000	-260,000	356,000	-17,000	305,000	242,000	129,000		143,000	84,000	7,000		-20,000	-262,000	526,000
cash paid in connection with operating lease liabilities							3,325,000	3,365,000	1,841,000	3,897,000	2,957,000	4,805,000	3,343,000	3,746,000	4,176,000	2,187,000	2,483,000	4,248,000	2,003,000	2,632,000	2,587,000	2,538,000	1,366,000	1,515,000	1,365,000	1,724,000
right-of-use assets obtained in exchange of operating lease obligations							1,683,000	0			25,153,000				983,000	0							0	0	0	19,461,000
offering expenses included in accounts payable and accrued expenses
remeasurement of operating lease liabilities and right-of-use assets due to lease modification										-3,781,000
realized gain on corporate equity securities
non-cash research and development expenses																																	0	5,000,000
proceeds from sale of corporate equity securities
issuance of common stock for settlement of success payments																		27,500,000										0	0	9,530,000
offering costs included in accounts payable and accrued expenses																		10,000		-124,000								0	3,000	19,000
unrealized gain on corporate equity securities																				1,416,000	-7,192,000	-7,333,000
non-cash investment in equity securities																											0	0
payments on construction financing lease obligation																											-236,000	-211,000	-207,000	-203,000		-175,000	53,000	-443,000
reclassification of liability for common stock subject to repurchase																											0	0	1,000	3,000		3,000	3,000	3,000		2,000	3,000	3,000
issuance of common stock for repayment of notes payable
issuance of common stock for asset acquisition																											0	0
receivable of proceeds from offering of common stock
issuances of common stock under benefit plans																							337,000	0			318,000	0
payments of notes payable
non-cash research and development expense																												0	12,500,000	1,942,000
right-of-use asset																								-204,000	1,003,000	981,000
operating lease liability																								218,000	-946,000	-1,379,000
net decrease in cash and cash equivalents																												-20,223,000
cash, cash equivalents and restricted cash, beginning of period																								0	0	136,395,000		0	0	148,249,000
cash, cash equivalents and restricted cash, end of period																								-105,833,000	52,673,000	159,551,000		-20,223,000	-85,747,000	219,290,000
issuance of common stock for settlement of notes payable																												0
adjustment to deferred revenue for revenue adoption																														474,000
net increase in cash and cash equivalents																									52,673,000	23,156,000				71,041,000	60,088,000	-57,554,000	-207,456,000	166,229,000	-14,551,000	-17,776,000	-11,554,000	86,024,000
receivable of proceeds from exercise of stock options
issuance of common stock for settlement of liabilities
re-measurement of warrant to purchase redeemable securities																																					0	87,000
accretion of redeemable convertible preferred stock to redemption value																																				0	0	47,000
reclassification of warrants to additional paid in capital
conversion of preferred stock to common stock upon closing of the initial public offering																																				0	0	199,915,000
payments of notes payables
net cash provided by:
operating activities
investing activities
financing activities
changes in restricted cash																																				0	0	-1,619,000
proceeds from public offering of common stock, net of issuance costs																																0	-417,000	97,102,000
cash and cash equivalents, beginning of period																																0	0	185,323,000		0	0	143,180,000
offering costs incurred but unpaid at period end																																		397,000
non-cash interest expense
changes in fair value of warrant liability
change in fair value of preferred stock tranche asset or liability
changes in fair value of anti-dilutive protection liability
changes in deferred rent																																				110,000	110,000	45,000
proceeds from equipment loan, net of issuance costs
proceeds from the issuance of redeemable convertible preferred stock and tranche rights, net of issuance costs
payments of equipment loan principal
proceeds from the issuance of common stock and restricted stock
proceeds from initial public offering of common stock, net of issuance costs																																				-196,000	-498,000	98,182,000
proceeds from stock option exercises																																				174,000	4,000	33,000
capitalization of construction-in-progress related to facility lease obligation																																				9,919,000	11,027,000	11,649,000
initial public offering costs incurred but unpaid at period end																																					-301,000	497,000
reclassification of warrants to additional paid-in capital																																				0	0	376,000
conversion of anti-dilutive protection liability to common stock
reclassification of preferred stock tranche liability upon settlement
accrual of final payment fee on equipment loan and debt discount
non-cash loss on debt extinguishment
payments of final fee for loan payoff
payments of initial public offering costs
cash paid for interest

We provide you with 20 years of cash flow statements for Editas Medicine stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Editas Medicine stock. Explore the full financial landscape of Editas Medicine stock with our expertly curated income statements.

The information provided in this report about Editas Medicine stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.